natgillin/translations-raw huggingface dataset:
The Diovan Reduction of Proteinuria (DROP) study further examined the efficacy of valsartan in reducing UAE in 391 hypertensive patients (BP=150/ 88 mmHg) with type 2 diabetes, albuminuria (mean=102 µg/ min; 20-700 µg/ min) and preserved renal function (mean serum creatinine = 80 µmol/ l).
V študiji zmanjševanja proteinurije z zdravilom Diovan (Diovan Reduction of Proteinuria - DROP) so naprej preučevali učinkovitost valsartana pri zmanjšanju izločanja albumina z urinom pri 391 hipertenzivnih bolnikih (s krvnim tlakom 150/ 88 mmHg), s sladkorno boleznijo tipa 2, z albuminurijo (v povprečju 102 µg/ min; v obsegu 20- 700 µg/ min) in z ohranjenim delovanjem ledvic (s povprečno koncentracijo kreatinina v serumu 80 µmol/ l).
Patients were randomized to one of 3 doses of valsartan (160, 320 and 640 mg/ od) and treated for 30 weeks.
Bolniki so bili randomizirani v eno od 3 skupin z odmerki valsartana 160, 320 ali 640 mg enkrat na dan, ki so jih prejemali 30 tednov.
At 30 weeks, the percentage change in UAE was significantly reduced by 36% from baseline with valsartan 160 mg (95%CI:
Po 30 tednih je bila z valsartanom 160 mg sprememba izločanja albumina z urinom v odstotkih značilno manjša za 36% od izhodiščne vrednosti (95% IZ:
22 to 47%), and by 44% with valsartan 320 mg (95%CI:
22 do 47%), z valsartanom 320 mg pa za 44% (95% IZ:
31 to 54%).
31 do 54%).
It was concluded that 160-320 mg of valsartan produced clinically relevant reductions in UAE in hypertensive patients with type 2 diabetes.
Zaključili so, da je 160- 320 mg valsartana doseže klinično pomembno zmanjšanje izločanja albumina z urinom pri hipertenzivnih bolnikih s sladkorno boleznijo tipa 2.
Recent myocardial infarction The VALsartan In Acute myocardial iNfarcTion trial (VALIANT) was a randomised, controlled, multinational, double-blind study in 14,703 patients with acute myocardial infarction and signs, symptoms or radiological evidence of congestive heart failure and/ or evidence of left ventricular systolic dysfunction (manifested as an ejection fraction ≤ 40% by radionuclide ventriculography or ≤ 35% by echocardiography or ventricular contrast angiography).
Nedavni miokardni infarkt VALIANT (VALsartan In Acute myocardial iNfarcTion) je bila randomizirana, kontrolirana, multinacionalna, dvojno slepa študija, v kateri je sodelovalo 14. 703 bolnikov z akutnim miokardnim infarktom, ki so imeli znake, simptome ali radiološke dokaze kongestivnega srčnega popuščanja in/ ali znake sistolične disfunkcije levega prekata (kar se kaže kot iztisna frakcija ≤ 40% pri rentgenski ventrikulografiji
There was no difference between valsartan and captopril in all-cause mortality based on age, gender,
Kombinacija valsartana s kaptoprilom ni prinesla dodatnih koristi v primerjavi z uporabo samo kaptoprila. Med valsartanom in kaptoprilom ni bilo razlik glede umrljivosti iz vseh vzrokov po starosti, spolu, rasi, predhodnem zdravljenju in osnovni bolezni.
Regarding renal function, doubling of serum creatinine was observed in 4.2% of valsartan-treated patients, 4.8% of valsartan+captopril-treated patients, and 3.4% of captopril- treated patients.
Glede delovanja ledvic so opazili podvojitev koncentracije kreatinina v serumu pri 4, 2% bolnikov, ki so se zdravlili z valsartanom, pri 4, 8% bolnikov, ki so se zdravili s kombinacijo valsartana in kaptoprila, in pri 3, 4% bolnikov, ki so se zdravili s kaptoprilom.
There was no difference in all-cause mortality, cardiovascular mortality or morbidity when beta blockers were administered together with the combination of valsartan + captopril, valsartan alone, or captopril alone.
Pri sočasni uporabi antagonistov adrenergičnih receptorjev beta v kombinaciji z valsartanom in kaptoprilom, skupaj samo z valsartanom ali skupaj samo s kaptoprilom ni bilo razlik v umrljivosti iz vseh vzrokov ter v kardiovaskularni umrljivosti in obolevnosti.
Heart failure Val-HeFT was a randomised, controlled, multinational clinical trial of valsartan compared with placebo on morbidity and mortality in 5,010 NYHA class II (62%), III (36%) and IV (2%) heart failure patients receiving usual therapy with LVEF< 40% and left ventricular internal diastolic diameter (LVIDD) > 2.9 cm/m2.
Srčno popuščanje Val- HeFT je bila randomizirana, kontrolirana, multinacionalna klinična študija valsartana v primerjavi s placebom glede obolevnosti in umrljivosti pri 5. 010 bolnikih s srčnim popuščanjem razreda NYHA II (62%), III (36%) in IV (2%), ki so prejemali običajno terapijo in so imeli iztisni delež levega prekata < 40% in notranji diastolični premer levega prekata (left ventricular internal diastolic diameter - LVIDD) > 2, 9 cm/ m2.
25.4% in valsartan group) were observed for those patients receiving the triple combination of an ACE inhibitor, a beta blocker and valsartan.
Opazili so rezultate v korist placebo (sestavljena umrljivost in obolevnost je bila 21, 9% pri placebu v primerjavi s 25, 4% v skupini z valsartanom) Pri bolnikih, ki so prejemali trojno kombinacijo zaviralca ACE, antagonista adrenergičnih receptorjev beta in valsartana, so opažali rezultate v korist placeba (umrljivost in obolevnost skupaj 21, 9% v skupini s placebom v primerjavi s 25, 4% v skupini z valsartanom).
In the overall Val-HeFT population, valsartan treated patients showed significant improvement in NYHA class, and heart failure signs and symptoms, including dyspnoea, fatigue, oedema and rales compared to placebo.
38 V celotni populaciji študije Val- HeFT se je pri bolnikih, zdravljenih z valsartanom, pokazalo značilno izboljšanje po razvrstitvi NYHA in v znakih ter simptomih srčnega popuščanja, vključno z dispnejo, utrujenostjo, edemom in s piskanjem pri dihanju v primerjavi s placebom.
40 Abrupt withdrawal of Diovan has not been associated with rebound hypertension or other adverse clinical events.
Po nenadni prekinitvi jemanja zdravila Diovan ni prišlo do povratne hipertenzije ali drugih neželenih kliničnih dogodkov.
Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2– 4 hours.
Po peroralni uporabi samo valsartana doseže ta najvišjo koncentracijo v plazmi v 2– 4 urah.
Food decreases exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (C max) by about 50%, although from about 8 h post dosing plasma valsartan concentrations are similar for the fed and fasted groups.
Hrana zmanjša izpostavljenost valsartanu (merjeno z AUC) za okrog 40% in njegovo najvišjo koncentracijo v plazmi (C max) za okrog 50%, vendar pa je od približno 8. ure po odmerjanju koncentracija valsartana v plazmi približno enaka pri skupini preiskovancev, ki so jedli, in pri tistih, ki so vzeli zdravilo na tešče.
Biotransformation:
39 Biotransformacija:
Valsartan is not biotransformed to a high extent as only about 20% of dose is recovered as metabolites.
Valsartan se biološko ne transformira v veliki meri, saj je le približno 20% odmerka mogoče prestreči v obliki metabolitov.
A hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the valsartan AUC).
V plazmi so ugotovili majhno koncentracijo hidroksimetabolita (manj kot 10% AUC valsartana).
Valsartan shows multiexponential decay kinetics (t ½α < 1 h and t ½ß about 9 h).
Valsartan kaže multieksponentno kinetiko upadanja (t ½α < 1 ura in t ½ß približno 9 ur).
Valsartan is primarily eliminated by biliary excretion in faeces (about 83% of dose) and renally in urine (about 13% of dose), mainly as unchanged drug.
Valsartan se izloča predvsem z blatom (približno 83% odmerka) in preko ledvic z urinom (približno 13% odmerka), večinoma v obliki nespremenjenega zdravila.
Following intravenous administration, plasma clearance of valsartan is about 2 l/ h and its renal clearance is 0.62 l/ h (about 30% of total clearance).
Po intravenski uporabi je plazemski očistek valsartana približno 2 l/ uro, njegov ledvični očistek pa 0, 62 l/ uro (približno 30% celotnega očistka).
AUC and C max values of valsartan are almost proportional with increasing dose over the clinical dosing range (40 to 160 mg twice a day).
Vrednosti AUC in C max valsartana se povečujejo linearno in so v mejah kliničnega odmerjanja (40 do 160 mg dvakrat na dan) skoraj sorazmerne večanju odmerka.
The average accumulation factor is about 1.7.
Povprečni akumulacijski faktor je okrog 1, 7.
The apparent clearance of valsartan following oral administration is approximately 4.5 l/ h.
Navidezni očistek valsartana po peroralni aplikaciji je približno 4, 5 l/ h.
41 In Heart failure patients:
Pri bolnikih s srčnim popuščanjem:
Special populations Elderly A somewhat higher systemic exposure to valsartan was observed in some elderly subjects than in young subjects; however, this has not been shown to have any clinical significance.
Posebne skupine bolnikov Starejši bolniki Pri nekaterih starejših bolnikih so opazili nekoliko večjo sistemsko izpostavljenost valsartanu v primerjavi z mladimi osebami; vendar se ni pokazalo, da bi imelo to kakšen kliničen pomen.
Impaired renal function As expected for a compound where renal clearance accounts for only 30% of total plasma clearance, no correlation was seen between renal function and systemic exposure to valsartan.
Okvarjeno delovanje ledvic V skladu s pričakovanji za spojino, katere ledvični očistek predstavlja samo 30% celotnega očistka plazme, niso našli nikakršne korelacije med delovanjem ledvic in sistemsko izpostavljenostjo valsartanu.
Dose adjustment is therefore not required in patients with renal impairment (creatinine clearance > 10 ml/ min).
Zato pri bolnikih z okvarjenim delovanjem ledvic odmerka ni treba prilagajati (očistek kreatinina > 10 ml/ min).
There is currently no experience on the safe use in patients with a creatinine clearance < 10 ml/ min and patients undergoing dialysis, therefore valsartan should be used with caution in these patients (see sections 4.2 and 4.4).
Trenutno ni izkušenj o varni uporabi pri bolnikih z očistkom kreatinina < 10 ml/ min in pri bolnikih, ki se zdravijo z dializo, zato je treba pri teh bolnikih valsartan uporabljati previdno (glejte poglavji 4. 2 in 4. 4).
Hepatic impairment Approximately 70% of the dose absorbed is eliminated in the bile, essentially in the unchanged form.
Jetrna okvara Okrog 70% absorbiranega odmerka se izloči z žolčem, večinoma v obliki nespremenjene spojine.
Diovan has not been studied in patients with severe hepatic dysfunction (see sections 4.2, 4.3 and 4.4).
Študij z zdravilom Diovan pri bolnikih z hudo okvaro jeter (glejte poglavja 4. 2, 4. 4 in 4. 4) niso izvedli.
In rats, maternally toxic doses (600 mg/ kg/ day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6).
Pri podganah so odmerki, toksični za mater, (600 mg/ kg/ dan) v zadnjih dneh brejosti in med dojenjem povzročili zmanjšano preživetje, nižjo telesno maso, upočasnitev razvoja (neprirasel uhelj in odprt ušesni kanal) (glejte poglavje 4. 6) pri potomstvu.
These doses in rats (600 mg/ kg/ day) are approximately 18 times the maximum recommended human dose on a mg/ m2 basis (calculations assume an oral dose of 320 mg/ day and a 60-kg patient).
Ti odmerki pri podganah (600 mg/ kg/ dan) so približno 18- krat večji od največjega priporočenega odmerka za ljudi na osnovi mg/ m2 (izračun predvideva peroralni odmerek 320 mg/ dan in 60- kg bolnika).
In non-clinical safety studies, high doses of valsartan (200 to 600 mg/ kg body weight) caused in rats a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit) and evidence of changes in renal haemodynamics (slightly raised plasma urea, and renal tubular hyperplasia and basophilia in males).
40 V nekliničnih študijah varnosti so visoki odmerki valsartana (200 do 600 mg/ kg telesne mase) pri podganah povzročili zmanjšanje parametrov rdečih krvnih celic (ertirocitov, hemoglobina, hematokrita) in znake spremenjene ledvične hemodinamike (nekoliko zvišana sečnina v plazmi in hiperplazija ledvičnih tubulov ter bazofilija pri samcih).
These doses in rats (200 and 600 mg/ kg/ day) are approximately 6 and 18 times the maximum recommended human dose on a mg/ m2 basis (calculations assume an oral dose of 320 mg/ day and a 60-kg patient).
Ti odmerki pri podganah (200 do 600 mg/ kg/ dan) so približno 6- krat in 18- krat večji od največjega priporočenega odmerka za ljudi na osnovi mg/ m2 (izračun predvideva peroralni odmerek 320 mg/ dan in 60- kg bolnika).
42 [To be completed nationally]
[Izpolni država članica]
[To be completed nationally]
41 [Izpolni država članica]
43 LABELLING
OZNAČEVANJE
44 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
42 PODATKI NA ZUNANJI OVOJNINI
Diovan and associated names (see Annex I) 40 mg film-coated tablets Valsartan Diovan and associated names (see Annex I) 40 mg capsules, hard Valsartan Diovan and associated names (see Annex I) 80 mg film-coated tablets Valsartan Diovan and associated names (see Annex I) 80 mg capsules, hard Valsartan Diovan and associated names (see Annex I) 160 mg film-coated tablets Valsartan Diovan and associated names (see Annex I) 160 mg capsules, hard Valsartan Diovan and associated names (see Annex I) 320 mg film-coated tablets Valsartan
Diovan in sorodna imena (glejte Dodatek I) 40 mg filmsko obložene tablete Valsartan Diovan in sorodna imena (glejte Dodatek I) 40 mg trde kapsule Valsartan Diovan in sorodna imena (glejte Dodatek I) 80 mg filmsko obložene tablete Valsartan Diovan in sorodna imena (glejte Dodatek I) 80 mg trde kapsule Valsartan Diovan in sorodna imena (glejte Dodatek I) 160 mg filmsko obložene tablete Valsartan Diovan in sorodna imena (glejte Dodatek I) 160 mg trde kapsule Valsartan Diovan in sorodna imena (glejte Dodatek I) 320 mg filmsko obložene tablete Valsartan
46 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
44 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU
Diovan and associated names (see Annex I) 40 mg film-coated tablets Valsartan Diovan and associated names (see Annex I) 40 mg capsules, hard Valsartan Diovan and associated names (see Annex I) 80 mg film-coated tablets Valsartan Diovan and associated names (see Annex I) 80 mg capsules, hard Valsartan Diovan and associated names (see Annex I) 160 mg film-coated tablets Valsartan Diovan and associated names (see Annex I) 160 mg capsules, hard Valsartan Diovan and associated names (see Annex I) 320 mg film-coated tablets Valsartan [See Annex I - To be completed nationally]
Diovan in sorodna imena (glejte Dodatek I) 40 mg filmsko obložene tablete Valsartan Diovan in sorodna imena (glejte Dodatek I) 40 mg trde kapsule Valsartan Diovan in sorodna imena (glejte Dodatek I) 80 mg filmsko obložene tablete Valsartan Diovan in sorodna imena (glejte Dodatek I) 80 mg trde kapsule Valsartan Diovan in sorodna imena (glejte Dodatek I) 160 mg filmsko obložene tablete Valsartan Diovan in sorodna imena (glejte Dodatek I) 160 mg trde kapsule Valsartan Diovan in sorodna imena (glejte Dodatek I) 320 mg filmsko obložene tablete Valsartan [Glejte Dodatek I – Izpolni država članica]
47 PACKAGE LEAFLET
45 NAVODILO ZA UPORABO
Diovan and associated names (see Annex I) 40 mg film-coated tablets Diovan and associated names (see Annex I) 40 mg capsules, hard Diovan and associated names (see Annex I) 80 mg film-coated tablets Diovan and associated names (see Annex I) 80 mg capsules, hard Diovan and associated names (see Annex I) 160 mg film-coated tablets Diovan and associated names (see Annex I) 160 mg capsules, hard Diovan and associated names (see Annex I) 320 mg film-coated tablets [See Annex I -To be completed nationally] Valsartan
Diovan in sorodna imena (glejte Dodatek I) 40 mg filmsko obložene tablete Diovan in sorodna imena (glejte Dodatek I) 40 mg trde kapsule Diovan in sorodna imena (glejte Dodatek I) 80 mg filmsko obložene tablete Diovan in sorodna imena (glejte Dodatek I) 80 mg trde kapsule Diovan in sorodna imena (glejte Dodatek I) 160 mg filmsko obložene tablete Diovan in sorodna imena (glejte Dodatek I) 160 mg trde kapsule Diovan in sorodna imena (glejte Dodatek I) 320 mg filmsko obložene tablete [Glejte Dodatek I – Izpolni država članica] valsartan
Read all of this leaflet carefully before you start taking this medicine.  Keep this leaflet.
Pred začetkom jemanja natančno preberite navodilo!  Navodilo shranite.
You may need to read it again.  If you have any further questions, ask your doctor or pharmacist.  This medicine has been prescribed for you.
Morda ga boste želeli ponovno prebrati.  Če imate dodatna vprašanja, se posvetujte z zdravnikom ali s farmacevtom.  Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
It may harm them, even if their symptoms are the same as yours.  If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Njim bi lahko celo škodovalo, čeprav imajo znake bolezni, podobne vašim.  Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
What Diovan is and what it is used for 2.
Kaj je zdravilo Diovan in za kaj ga uporabljamo 2.
Before you take Diovan 3.
Kaj morate vedeti, preden boste vzeli zdravilo Diovan 3.
How to take Diovan 4.
Kako jemati zdravilo Diovan 4.
How to store Diovan 6.
Shranjevanje zdravila Diovan 6.
Diovan 40 mg film-coated tablets can be used for two different conditions:  to treat people after a recent heart attack (myocardial infarction). “ Recent” here means between 12 hours and 10 days.  to treat symptomatic heart failure.
"Nedavni" to pomeni pred 12 urami do 10 dnevi.  Za zdravljenje simptomatskega srčnega popuščanja.
Diovan is used when a group of medicines called Angiotensin Converting Enzyme (ACE) inhibitors (a medication to treat heart failure) cannot be used or it may be used in addition to ACE inhibitors when beta blockers (another medication to treat heart failure) cannot be used.
Zdravilo Diovan uporabimo takrat, kadar ne moremo uporabiti zdravil iz skupine, ki se imenujejo zaviralci angiotenzinske konvertaze (ACE) (zdravila pri zdravljenju srčnega popuščanja), lahko pa ga uporabimo poleg zaviralcev ACE, kadar ne moremo uporabiti antagonistov adrenergičnih receptorjev beta (druga vrsta zdravil pri zdravljenju srčnega popuščanja).
Diovan 40 mg capsules, hard can be used for two different conditions:  to treat people after a recent heart attack (myocardial infarction). “ Recent” here means between 12 hours and 10 days.  to treat symptomatic heart failure.
"Nedavni" pri tem pomeni pred 12 urami do 10 dnevi.  Za zdravljenje simptomatskega srčnega popuščanja.
Diovan is used when a group of medicines called Angiotensin Converting Enzyme (ACE) inhibitors (a medication to treat heart failure) cannot be used or it may be used in addition to ACE inhibitors when beta blockers (another medication to treat heart failure)
Zdravilo Diovan uporabimo takrat, kadar ne moremo uporabiti zdravila iz skupine, ki se imenuje zaviralci angiotenzinske konvertaze (ACE) (zdravila pri zdravljenju srčnega popuščanja), lahko pa ga uporabimo poleg zaviralca ACE, kadar ne
49 cannot be used.
47 moremo uporabiti antagoniste adrenergičnih receptorjev beta (druga vrsta zdravil pri zdravljenju srčnega popuščanja).
Diovan 80 mg film-coated tablets can be used for three different conditions:  to treat high blood pressure.
Diovan 80 mg filmsko obložene tablete je mogoče uporabljati pri zdravljenju treh bolezni:  Za zdravljenje visokega krvnega tlaka.
Lowering your blood pressure to normal reduces the risk of developing these disorders.  to treat people after a recent heart attack (myocardial infarction). “ Recent” here means between 12 hours and 10 days.  to treat symptomatic heart failure.
"Nedavni" to pomeni pred 12 urami do 10 dnevi.  Za zdravljenje simptomatskega srčnega popuščanja.
Diovan is used when a group of medicines called Angiotensin Converting Enzyme (ACE) inhibitors (a medication to treat heart failure) cannot be used or it may be used in addition to ACE inhibitors when beta blockers (another medication to treat heart failure) cannot be used.
Zdravilo Diovan uporabimo takrat, kadar ne moremo uporabiti zdravil iz skupine, ki se imenujejo zaviralci angiotenzinske konvertaze (ACE) (zdravila pri zdravljenju srčnega popuščanja), lahko pa ga uporabimo poleg zaviralca ACE, kadar ne moremo uporabiti antagoniste adrenergičnih receptorjev beta (druga vrsta zdravil pri zdravljenju srčnega popuščanja).
Diovan 80 mg capsules, hard can be used for three different conditions:  to treat high blood pressure.
Diovan 80 mg trde kapsule je mogoče uporabljati pri zdravljenju treh bolezni:  Za zdravljenje visokega krvnega tlaka.
Lowering your blood pressure to normal reduces the risk of developing these disorders.  to treat people after a recent heart attack (myocardial infarction). “ Recent” here means between 12 hours and 10 days.  to treat symptomatic heart failure.
"Nedavni" pri tem pomeni pred 12 urami do 10 dnevi.  Za zdravljenje simptomatskega srčnega popuščanja.
Diovan 160 mg film-coated tablets can be used for three different conditions:  to treat high blood pressure.
Diovan 160 mg filmsko obložene tablete je mogoče uporabljati pri zdravljenju treh bolezni:  Za zdravljenje visokega krvnega tlaka.
Diovan 160 mg capsules, hard can be used for three different conditions:  to treat high blood pressure.
Diovan 160 mg trde kapsule je mogoče uporabljati pri zdravljenju treh bolezni:
High blood pressure increases the workload on the heart and arteries.
48  Za zdravljenje visokega krvnega tlaka.
If not treated it can damage the blood vessels of the brain, heart, and kidneys, and may result in a stroke,
Visok krvni tlak povečuje obremenitev srca in arterij.
50 heart failure, or kidney failure.
Če ga ne zdravimo, lahko poškoduje krvne žile v možganih, srcu in ledvicah, kar lahko povzroči infarkt, srčno popuščanje ali odpoved ledvic.
Diovan 320 mg film-coated tablets can be used  to treat high blood pressure.
Diovan 320 mg filmsko obložene tablete je mogoče uporabljati:  Za zdravljenje visokega krvnega tlaka.
Do not take Diovan:  if you are allergic (hypersensitive) to valsartan or any of the other ingredients of Diovan.  if you have severe liver disease.  if you are more than 3 months pregnant (it is also better to avoid Diovan in early pregnancy - see pregnancy section).
Ne jemljite zdravila Diovan:  če ste alergični (preobčutljivi) na valsartan ali katerokoli sestavino zdravila Diovan,  če imate hudo bolezen jeter,  če ste noseči več kot 3 mesece (tudi v zgodnji nosečnosti raje ne jemljite zdravila Diovan) – glejte poglavje nosečnost.
If any of these apply to you, do not take Diovan
Če karkoli od zgoraj navedenega velja za vas, ne jemljite zdravila Diovan.
Take special care with Diovan:  if you have liver disease.  if you have severe kidney disease or if you are undergoing dialysis.  if you are suffering from a narrowing of the kidney artery.  if you have recently undergone kidney transplantation (received a new kidney).  if you are treated after a heart attack or for heart failure, your doctor may check your kidney function.  if you have severe heart disease other than heart failure or heart attack.  if you are taking medicines that increase the amount of potassium in your blood.
Bodite posebno pozorni pri uporabi zdravila Diovan:  če imate bolezen jeter,  če imate hude težave z ledvicami ali če se zdravite z dializo,  če imate zožanje ledvične arterije,  če so vam pred kratkim presadili ledvico (dobili ste novo ledvico),  če se zdravite po srčnem napadu ali zaradi srčnega popuščanja, bo morda zdravnik preveril delovanje vaših ledvic,  če imate hudo bolezen srca, razen srčnega popuščanja in srčnega napada,  če jemljete zdravila, ki povečujejo količino kalija v krvi.
It may be necessary to check the amount of potassium in your blood at regular intervals.  if you suffer from aldosteronism.
Morda bo treba v rednih intervalih preverjati količino kalija v vaši krvi,  če imate aldosteronizem.